Latent autoimmune diabetes in adults (LADA) should be less latent

Diabetologia

Volumn 48, Issue 11, 2005, Pages 2206-2212

  Fourlanos, S ^a   Dotta, F ^b   Greenbaum, C J ^c   Palmer, J P ^d   Rolandsson, O ^e   Colman, P G ^f   Harrison, L C ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF SIENA   (Italy)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UMEÅ UNIVERSITY   (Sweden)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Autoimmune diabetes; Classification; Diagnostic criteria; HLA; LADA; Latent autoimmune diabetes in adults; Type 1 diabetes

Indexed keywords

GLUCOSE; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INSULIN; ORAL ANTIDIABETIC AGENT;

AGE DISTRIBUTION; AUTOIMMUNE DISEASE; BODY MASS; CLINICAL FEATURE; DIABETES CONTROL; DIABETIC KETOACIDOSIS; DIABETIC MICROANGIOPATHY; DIABETOGENESIS; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; GENE LOCUS; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HLA SYSTEM; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LATENT PERIOD; LIFESTYLE; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC ACTIVATION; PANCREAS ISLET BETA CELL; PATIENT ATTITUDE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIZED NOMENCLATURE OF MEDICINE; TANDEM REPEAT;

ADULT; AGE FACTORS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; HLA ANTIGENS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIFE STYLE; TERMINOLOGY;

EID: 27744482032     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1960-7     Document Type: Review

References (58)

1. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362
2. Genovese S, Bonifacio E, McNally JM et al (1992) Distinct cytoplasmic islet cell antibodies with different risks for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35:385-388
3. Gianani R, Pugliese A, Bonner-Weir S et al (1992) Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes 41:347-353
4. Hagopian WA, Karlsen AE, Gottsater A et al (1993) Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64 K autoantibody positivity at onset predicts diabetes type. J Clin Invest 91:368-374
5. Turner R, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350:1288-1293
6. Lohmann T, Nietzschmann U, Kiess W (2000) 'Lady-like': is there a latent autoimmune diabetes in the young? Diabetes Care 23:1707-1708
7. Juneja R, Palmer JP (1999) Type 1 1/2 diabetes: myth or reality? Autoimmunity 29:65-83
8. Palmer JP, Hirsch IB (2003) What's in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 26:536-538
9. Pozzilli P, Di Mario U (2001) Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 24:1460-1467
10. Hosszufalusi N, Vatay A, Rajczy K et al (2003) Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452-457
11. Douek IF, Gillespie KM, Bingley PJ, Gale EA (2002) Diabetes in the parents of children with Type I diabetes. Diabetologia 45:495-501
12. Cosentino A, Gambelunghe G, Tortoioli C, Falorni A (2002) CTLA-4 gene polymorphism contributes to the genetic risk for latent autoimmune diabetes in adults. Ann N Y Acad Sci 958:337-440
13. Tuomi T, Carlsson A, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157
14. Takeda H, Kawasaki E, Shimizu I et al (2002) Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 25:995-1001
15. Gjessing HJ, Matzen LE, Pedersen PC, Faber OK, Froland A (1998) Insulin requirement in non-insulin-dependent diabetes mellitus: relation to simple tests of islet B-cell function and insulin sensitivity. Diabet Med 5:328-332
16. Leslie RD, Pozzilli P (1994) Type I diabetes masquerading as type II diabetes. Possible implications for prevention and treatment. Diabetes Care 17:1214-1219
17. Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay IR (2000) Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 17:667-674
18. Carlsson A, Sundkvist G, Groop L, Tuomi T (2000) Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 85:76-80
19. Zinman B, Kahn SE, Haffher SM, O'Neill MC, Heise MA, Freed MI (2004) Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 53:3193-3200
20. Karjalainen J, Salmela P, Ilonen J, Surcel HM, Knip M (1989) A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 320:881-886
21. Caillat-Zucman S, Garchon HJ, Timsit J et al (1992) Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 90:2242-2250
22. Tait BD, Harrison LC, Drummond BP, Stewart V, Varney MD, Honeyman MC (1995) HLA antigens and age at diagnosis of insulin-dependent diabetes mellitus. Hum Immunol 42:116-122
23. Cerna M, Novota P, Kolostova K et al (2003) HLA in Czech adult patients with autoimmune diabetes mellitus: comparison with Czech children with type 1 diabetes and patients with type 2 diabetes. Eur J Immunogenet 30:401-407
24. Bennett ST, Lucassen AM, Gougli SC et al (1995) Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 9:284-292
25. Pugliese A, Zeller M, Fernandez A Jr et al (1997) The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 15:293-297
26. Vafiadis P, Bennett ST, Todd JA et al (1997) Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 15:289-292
27. Matejkova-Behanova M, Vankova M, Hill M et al (2004) Polymorphism of INS VNTR is associated with glutamic acid decarboxylase antibodies and postprandial C-peptide in patients with onset of diabetes after 35 years of age. Physiol Res 53:187-190
28. Cerrone GE, Caputo M, Lopez AP et al (2004) Variable number of tandem repeats of the insulin gene determines susceptibility to latent autoimmune diabetes in adults. Mol Diagn 8:43-49
29. Gambelunghe G, Ghaderi M, Tortoioli C et al (2001) Two distinct MICA gene markers discriminate major autoimmune diabetes types. J Clin Endocrinol Metab 86:3754-3760
30. Vatay A, Rajczy K, Pozsonyi E et al (2002) Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus. Immunol Lett 84:109-115
31. Vauhkonen I, Niskanen L, Knip M et al (2000) Impaired insulin secretion in non-diabetic offspring of probands with latent autoimmune diabetes mellitus in adults. Diabetologia 43:69-78
32. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46:1701-1710
33. Verge CF, Stenger D, Bonifacio E et al (1998) Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. diabetes 47:1857-1866
34. Harrison LC (2001) Risk assessment, prediction and prevention of type 1 diabetes. Pediatric Diabetes 2:71-82
35. Kobayashi T, Tanaka S, Okubo M, Nakana, Murase T, Lernmark A (2003) Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly progressive type 1 diabetes. J Clin Endocrinol Metab 88:4678-4775
36. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP (1999) Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 48:983-988
37. Shimada A, Imazu Y, Morinaga S et al (1999) T-cell insulitis found in anti-GAD65+diabetes with residual beta-cell function. A case report. Diabetes Care 22:615-617
38. Weetman AP (2003) Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 148:1-9
39. Smith CM, Clarke CF, Porteous LE, Elsori H, Cameron DJ (2000) Prevalence of coeliac disease and longitudinal follow-up of antigliadin antibody status in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 1:199-203
40. Wagner R, Genovese S, Bosi E et al (1994) Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia 37:365-371
41. Radetti G, Paganini C, Gentili L et al (1995) Frequency of Hashimoto's thyroiditis in children with type 1 diabetes mellitus. Acta Diabetol 32:121-124
42. Hansen D, Bennedbaek FN, Hansen LK, Hoier-Madsen M, Jacobsen BB, Hegedus L (1999) Thyroid function, morphology and autoimmunity in young patients with insulin-dependent diabetes mellitus. Eur J Endocrinol 140:512-518
43. Gambelunghe G, Forini F, Laureti S et al (2000) Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 52:565-573
44. Kucera P, Novakova D, Behanova M, Novak J, Tlaskalova-Hogenova H, Andel M (2003) Gliadin, endomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA). Clin Exp Immunol 133:139-143
45. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G (1993) Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902-910
46. Kobayashi T, Nakanishi K, Murase T, Kosaka K (1996) Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45:622-626
47. Torn C, Landin-Olsson M, Ostman J, Schersten B, Arnqvist H, Blohme G et al (2000) Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes/Metab Res Rev 16:442-447
48. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G (2001) High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 86:3032-3038
49. Behme MT, Dupre J, Harris SB, Hramiak I, Mahon JL (2003) Insulin resistance in latent autoimmune diabetes of adulthood. Ann N Y Acad Sci 1005:374-377
50. Isomaa B, Almgren P, Henricsson M et al (1999) Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 22:1347-1353
51. Baum P, Hermann W, Verlohren HJ, Wagner A, Lohmann T, Grahmann F (2003) Diabetic neuropathy in patients with 'latent autoimmune diabetes of the adults' (LADA) compared with patients with type 1 and type 2 diabetes. J Neurol 250:682-687
52. The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517-523
53. Ridker PM (2003) High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 92:17K-22K
54. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865
55. UK Prospective Diabetes Study (UKPDS) Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569
56. Maruyama T, Shimada A, Kanatsuka A et al (2003) Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 1005:362-369
57. Uusitupa M, Louheranta A, Lindstrom J et al (2000) The finnish diabetes prevention study. Br J Nutr 83(Suppl 1):S137-S142
58. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403